What is the main purpose of this 8-K filing?

The primary purpose of this 8-K filing is to announce Boston Scientific Corporation's definitive agreement to acquire the Electrophysiology business of C.R. Bard Incorporated.

When is the acquisition expected to be completed?

The acquisition is anticipated to be completed in the second half of 2013, contingent upon meeting standard closing conditions.

What is the Electrophysiology (EP) business?

The Electrophysiology (EP) business focuses on products and technologies used to diagnose and treat heart rhythm disorders, a significant segment within cardiovascular medicine.

What are the key strategic implications of this acquisition for Boston Scientific?

This acquisition is a strategic move by Boston Scientific to strengthen its position in the growing Electrophysiology market, potentially enhancing its product offerings and market share in cardiovascular interventions.

BSX 8-K SEC Disclosure — Jun 28, 2013

Summary

Boston Scientific Corporation (BSX) has announced a significant strategic move with the signing of a definitive agreement to acquire the Electrophysiology (EP) business of C.R. Bard Incorporated. This acquisition is expected to close in the second half of 2013, subject to customary closing conditions. The EP business is a key area within cardiovascular intervention, and its integration into Boston Scientific's portfolio is likely to bolster its presence and competitive standing in this growing market segment.

Key Highlights

1Boston Scientific (BSX) to acquire the Electrophysiology (EP) business of C.R. Bard.
2The acquisition is expected to close in the second half of 2013.
3The transaction is subject to customary closing conditions.
4This move signals a strategic expansion for BSX in the cardiovascular intervention space.
5A press release dated June 28, 2013, detailing the acquisition, is included as an exhibit.

BOSTON SCIENTIFIC CORP 8-K Report, Corporate Update (Jun 28, 2013)

Summary

Key Highlights

Frequently Asked Questions